Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Tech for Wellbeing: Applications and Devices for a Better You - 2Grasping Various Kinds of Local misdemeanors
- 3'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- 4A definitive Manual for Internet Mastering and Expertise Improvement
- 5'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- Far-right German youth group delegates seek deportations, remigration
- German foreign minister backs abandoning EU's unanimity principle
- VPN Administrations for Online Protection
- Smooth countdown continues for Artemis II moon mission
- New Cheetos and Doritos will be free of artificial dyes
- Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
